1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6322EFFEF79F15E8A65257EA600428F75
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/medical-affairs-role-in-health-economics-outcomes-research-within-oncology?opendocument
18
19opendocument
2054.82.99.169
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Medical Affairs Health Outcomes

Medical Affairs’ Role in Health Economics & Outcomes Research within Oncology

ID: POP-264


Features:

11 Info Graphics

12 Data Graphics

180+ Metrics

7 Narratives


Pages: 38


Published: 2015


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
As payers and consumers place increasing emphasis on positive outcomes for patients' health, organizations are developing their health outcomes data generation and utilization skills. The Medical Affairs (MA) function plays a vital role in health outcomes (HO) information exchange between biopharmaceutical companies and key external stakeholders.

Development of strong HO capabilities within MA organizations requires increase in MA’s involvement with HO groups, development of field-based HO capabilities, customization of HO data according to stakeholders, and building real world data capabilities to generate and utilize HO information.

Best Practices, LLC undertook a study to help companies focused on oncology therapies find better ways to develop successful Health Outcomes groups. This research delivers current data and best practices from Medical Affairs leaders with an oncology focus at top biopharmaceutical companies.


Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Biopharmaceutical


Companies Profiled:
Astellas; AstraZeneca; Bayer; Insys Therapeutics; Incyte; Jazz Pharmaceuticals; Lilly; Onyx Pharmaceuticals; ProStrakan; Roche


Study Snapshot

This study engaged 10 executives from leading life sciences companies. The analysis is focused on companies with oncology therapies.

Key Findings

Longevity of HO Groups: HO programs are common, but they represent a young initiative for many of the benchmark class; sixty percent of companies have had it in place for less than three years.
Reporting Structure: 60% of companies’ HO groups report to Medical Affairs. A majority of the interviewed executives think that HO groups must report to a science and research oriented department such as clinical or medical affairs. Between these two, medical affairs provides better opportunities for needs assessment, communicating HO data insights, and interacting with key decision makers.

Table of Contents

Executive Summary pp. 3-9

    Research Objectives & Methodology pp. 3
    Participating Companies pp. 4
    Abbreviations pp. 5-6
    Key Findings & Insights pp. 7-9

Longevity of HO Groups pp. 10-11
HO Leadership pp. 12-13
HO Reporting Structure pp. 14-15
HO Group Staffing pp. 16-19
MA’s Role in HO Activities pp. 20-23
MA’s Role in Collecting HO Data pp. 24-25
Utilization of HO Data pp. 26-32
Impact of HO Data on Decisions pp. 33-36

List of Charts & Exhibits

Length of Health Outcomes (HO) Programs
HO Leadership Within Benchmark Class
Reporting Structure: To whom does the Health Outcomes group(s) report?
Number of Field and Office Based HO’s FTEs
Percentage of Field-Based HO FTEs
Core Field-Based HO Responsibilities
Medical Affair’s Involvement in HO Activities
Medical Affair’s Role in Collecting HO Data
Utilizing the Health Outcomes Data To Inform Patients
Utilizing the Health Outcomes Data To Inform Payers
Utilizing the Health Outcomes Data To Inform Providers
Effect of HO Data on Critical Decisions